Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG8) is a membrane-bound glycosyltransferase enzyme localized in the endoplasmic reticulum. It catalyzes the addition of the second glucose residue from dolichyl-phosphate-glucose to the growing lipid-linked oligosaccharide precursor during the N-linked glycosylation of proteins. This step is essential for the proper folding and maturation of glycoproteins. Mutations in ALG8 disrupt glycan assembly, leading to congenital disorder of glycosylation type Ih, characterized by a spectrum of developmental, neurologic, hepatic, and coagulation abnormalities. ALG8 also plays a role in the maturation and localization of PKD1/Polycystin-1 and has been implicated in polycystic liver disease. No approved drugs are known to specifically target ALG8. It is considered a clinically relevant enzyme in human glycoprotein biosynthesis[1][2][3][4].
Inhibition of glycosyltransferase activity (theoretical; no specific drugs currently identified)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG8).